I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And Molecular Analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

-
Investigator: Laura J. Esserman, MD
Sponsor: QuantumLeap Healthcare Collaborative

Location(s): United States

Description

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.